drug toxicity

Summary

Summary: Manifestations of the adverse effects of drugs administered therapeutically or in the course of diagnostic techniques. It does not include accidental or intentional poisoning for which specific headings are available.

Top Publications

  1. pmc Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
    Munir Pirmohamed
    Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3GE
    BMJ 329:15-9. 2004
  2. doi Systems pharmacology to predict drug toxicity: integration across levels of biological organization
    Jane P F Bai
    Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland 20993, USA
    Annu Rev Pharmacol Toxicol 53:451-73. 2013
  3. pmc Data-driven methods to discover molecular determinants of serious adverse drug events
    A P Chiang
    Department of Medicine, Stanford Center for Biomedical Informatics, Stanford University School of Medicine, Stanford, California, USA
    Clin Pharmacol Ther 85:259-68. 2009
  4. pmc Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study
    Min Zhang
    School of Population Health, University of Western Australia, Perth, WA, Australia
    BMJ 338:a2752. 2009
  5. pmc Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
    Holland C Detke
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    BMC Psychiatry 10:43. 2010
  6. ncbi Identifying and preventing adverse drug events in elderly hospitalised patients: a randomised trial of a program to reduce adverse drug effects
    C Trivalle
    Pole Vieillissement, Readaptation et Accompagnement, Hopital Paul Brousse, APHP, Villejuif, France
    J Nutr Health Aging 14:57-61. 2010
  7. doi Adverse drug reaction deaths reported in United States vital statistics, 1999-2006
    Greene Shepherd
    Eshelman School of Pharmacy, University of North Carolina, Asheville, USA
    Ann Pharmacother 46:169-75. 2012
  8. doi Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C
    Chung Feng Huang
    Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
    J Infect Dis 201:751-9. 2010
  9. ncbi Cisplatin nephrotoxicity
    Istvan Arany
    Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Semin Nephrol 23:460-4. 2003
  10. pmc A randomized trial of electronic clinical reminders to improve medication laboratory monitoring
    Michael E Matheny
    Division of General Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Am Med Inform Assoc 15:424-9. 2008

Detail Information

Publications333 found, 100 shown here

  1. pmc Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
    Munir Pirmohamed
    Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3GE
    BMJ 329:15-9. 2004
    ..To ascertain the current burden of adverse drug reactions (ADRs) through a prospective analysis of all admissions to hospital...
  2. doi Systems pharmacology to predict drug toxicity: integration across levels of biological organization
    Jane P F Bai
    Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland 20993, USA
    Annu Rev Pharmacol Toxicol 53:451-73. 2013
    To achieve sensitive and specific mechanism-based prediction of drug toxicity, the tools of systems pharmacology will be integrated using structured ontological approaches, analytics, mathematics, and statistics...
  3. pmc Data-driven methods to discover molecular determinants of serious adverse drug events
    A P Chiang
    Department of Medicine, Stanford Center for Biomedical Informatics, Stanford University School of Medicine, Stanford, California, USA
    Clin Pharmacol Ther 85:259-68. 2009
    ..We also describe recent examples of how bioinformatics methods coupled with data repositories can advance the science of SADRs...
  4. pmc Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study
    Min Zhang
    School of Population Health, University of Western Australia, Perth, WA, Australia
    BMJ 338:a2752. 2009
    ..To identify factors that predict repeat admission to hospital for adverse drug reactions (ADRs) in older adults...
  5. pmc Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
    Holland C Detke
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    BMC Psychiatry 10:43. 2010
    ..During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation was identified in a small percentage of patients following injection with olanzapine LAI...
  6. ncbi Identifying and preventing adverse drug events in elderly hospitalised patients: a randomised trial of a program to reduce adverse drug effects
    C Trivalle
    Pole Vieillissement, Readaptation et Accompagnement, Hopital Paul Brousse, APHP, Villejuif, France
    J Nutr Health Aging 14:57-61. 2010
    ..Evaluate the impact of educational intervention in decreasing ADEs in elderly patients in a hospital setting...
  7. doi Adverse drug reaction deaths reported in United States vital statistics, 1999-2006
    Greene Shepherd
    Eshelman School of Pharmacy, University of North Carolina, Asheville, USA
    Ann Pharmacother 46:169-75. 2012
    ..Adverse drug reactions (ADRs) are an important source of morbidity and mortality during medical care...
  8. doi Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C
    Chung Feng Huang
    Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
    J Infect Dis 201:751-9. 2010
    ..The present study evaluated the efficacy and safety of pegylated interferon (PegIFN)/ribavirin treatment in elderly patients with hepatitis C virus (HCV) infection...
  9. ncbi Cisplatin nephrotoxicity
    Istvan Arany
    Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Semin Nephrol 23:460-4. 2003
    ..Manipulation of these responses may be exploited to reduce its toxicity clinically...
  10. pmc A randomized trial of electronic clinical reminders to improve medication laboratory monitoring
    Michael E Matheny
    Division of General Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Am Med Inform Assoc 15:424-9. 2008
    ..We evaluated the impact of electronic reminders delivered to primary care physicians on rates of appropriate routine medication laboratory monitoring...
  11. doi Effect of an electronic medication reconciliation application and process redesign on potential adverse drug events: a cluster-randomized trial
    Jeffrey L Schnipper
    Harvard Medical School, Division of General Medicine, Brigham and Women s Hospital, 1620 Tremont St, Boston, MA 02120 1613, USA
    Arch Intern Med 169:771-80. 2009
    ..We sought to measure the impact of an information technology-based medication reconciliation intervention on medication discrepancies with potential for harm (potential adverse drug events [PADEs])...
  12. pmc A basic study design for expedited safety signal evaluation based on electronic healthcare data
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Pharmacoepidemiol Drug Saf 19:858-68. 2010
    ....
  13. pmc The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty
    Miran Brvar
    Poison Control Centre, University Medical Centre Ljubljana, Ljubljana, Slovenia
    BMC Clin Pharmacol 9:8. 2009
    ....
  14. doi Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project
    Preciosa M Coloma
    Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
    Pharmacoepidemiol Drug Saf 20:1-11. 2011
    ..In this proof-of-concept paper we describe the framework, process, and preliminary results of combining data from European electronic healthcare record (EHR) databases for large-scale monitoring of drug safety...
  15. pmc Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome
    Lun Yang
    Bio X Center, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders Ministry of Education, Shanghai Jiao Tong University, Shanghai, China
    PLoS Comput Biol 5:e1000441. 2009
    ..In conclusion, SADR targets and the patient-specific off-targets could be identified through a systematic investigation of the CPI, generating important hypotheses for prospective experimental validation of the candidate genes...
  16. pmc Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients
    Eva Gross
    Department of Gynecology, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
    PLoS ONE 3:e4003. 2008
    ..As known deleterious mutations explain only a limited proportion of the drug-adverse events, we systematically searched for additional DPYD variations associated with enhanced drug toxicity.
  17. doi A microfluidic 3D hepatocyte chip for drug toxicity testing
    Yi Chin Toh
    Institute of Bioengineering and Nanotechnology, A STAR, The Nanos, Singapore, 138669, Singapore
    Lab Chip 9:2026-35. 2009
    We have developed a microfluidic 3D hepatocyte chip (3D HepaTox Chip) for in vitro drug toxicity testing to predict in vivo drug hepatotoxicity...
  18. pmc Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case study
    Lun Yang
    Bio X Center, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders Ministry of Education, Shanghai Jiao Tong University, Shanghai, China
    PLoS Comput Biol 7:e1002016. 2011
    ....
  19. doi Renal vulnerability to drug toxicity
    Mark A Perazella
    Section of Nephrology, Department of Medicine, Yale University, New Haven, Connecticut 06520 8029, USA
    Clin J Am Soc Nephrol 4:1275-83. 2009
    ..Recognizing risk factors that increase renal vulnerability to drug-induced kidney disease is the first step in reducing the renal complications of drugs and toxins...
  20. doi microRNAs as mediators of drug toxicity
    Tsuyoshi Yokoi
    Department of Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa 920 1192, Japan
    Annu Rev Pharmacol Toxicol 53:377-400. 2013
    ....
  21. doi Prevalence of adverse events in pediatric intensive care units in the United States
    Swati Agarwal
    Virginia Commonwealth University School of Medicine, Inova Campus, Pediatric Critical Care, Inova Fairfax Hospital for Children, Falls Church, VA, USA
    Pediatr Crit Care Med 11:568-78. 2010
    ....
  22. pmc Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism
    David P McDonnell
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    BMC Psychiatry 10:45. 2010
    ..The authors conducted a series of parallel investigations into the possible reasons PDSS events occur...
  23. pmc Post-approval drug safety surveillance
    Robert D Gibbons
    Center for Health Statistics, University of Illinois at Chicago, Chicago, Illinois 60612, USA
    Annu Rev Public Health 31:419-37. 2010
    ..Many of these methodologies are then illustrated through application to data on the possible relationship between taking antidepressants and increased risk of suicidality...
  24. pmc Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans
    Zachary A Marcum
    Departments of Geriatrics, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Am Geriatr Soc 60:34-41. 2012
    ....
  25. doi FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable?
    Garry G Graham
    Department of Clinical Pharmacology, St Vincent s Hospital, Darlinghurst, NSW, 2010, Australia
    Inflammopharmacology 18:47-55. 2010
    ..Adoption of these two recommendations may lead to the increased use of NSAIDs with the potential of increasing incidence of NSAIDs-related adverse reactions...
  26. pmc Review of pyronaridine anti-malarial properties and product characteristics
    Simon L Croft
    Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
    Malar J 11:270. 2012
    ..falciparum malaria and blood stage P. vivax malaria with the name of Pyramax® and has received Positive Opinion by European Medicines Agency under the Article 58 procedure...
  27. doi Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study
    Joanne M Langley
    Canadian Center for Vaccinology, Dalhousie University and IWK Health Centre Halifax, Halifax, Nova Scotia, B3K 6R8, Canada
    Vaccine 30:3389-94. 2012
    ..We conducted a pre-season study of 2010-2011 TIV safety and immunogenicity in children 12-59 months of age to inform public health decision making...
  28. pmc Adverse drug reactions related hospital admissions in persons aged 60 years and over, The Netherlands, 1981-2007: less rapid increase, different drugs
    Klaas A Hartholt
    Section of Geriatric Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    PLoS ONE 5:e13977. 2010
    ..Because of raised awareness of ADR, a decrease in ADR might be expected. The aim of this study was to determine trends in ADR-related hospitalizations in the older Dutch population...
  29. pmc Perceived adverse drug reactions among non-institutionalized children and adolescents in Germany
    Hildtraud Knopf
    RKI 22, Robert Koch Institute, General Pape Strasse 64 66, 12101 Berlin, Germany
    Br J Clin Pharmacol 70:409-17. 2010
    ..7% to 2.7% among paediatric outpatients and from 2.6% to 18.1% among paediatric inpatients. Little has been reported on the risks of drug use in the general child population...
  30. pmc Performance and safety of praziquantel for treatment of intestinal schistosomiasis in infants and preschool children
    José C Sousa-Figueiredo
    Disease Control Strategy Group, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
    PLoS Negl Trop Dis 6:e1864. 2012
    ..We have formally assessed parasitological cure and putative side-effects in a prospective cohort of Schistosoma mansoni-infected children (aged 5 months-7 years old) in lakeshore settings of Uganda...
  31. doi Adverse drug reactions in patients in an Iranian department of internal medicine
    Sara Pourseyed
    Immunology, Asthma and Allergy Research Institute, Children Medical Center, Medical Sciences University of Tehran, Tehran, IR Iran
    Pharmacoepidemiol Drug Saf 18:104-10. 2009
    ..The department of internal medicine is not an exception to this issue. This study was performed to determine the nature and frequency of ADRs in an internal medicine ward in Iran...
  32. ncbi Drug toxicity in the neonate
    John McIntyre
    Academic Division of Child Health, University of Nottingham, Derbyshire Children s Hospital, Derby, UK
    Biol Neonate 86:218-21. 2004
    ..This therefore predisposes to certain types of drug toxicity, which are described below...
  33. pmc Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events
    Marco Guerrini
    Istituto di Ricerche Chimiche e Biochimiche G Ronzoni, Città Studi, via Giuseppe, Colombo 81, 20133 Milan, Italy
    Nat Biotechnol 26:669-75. 2008
    ..Our analysis suggests effective screening methods that can be used to determine whether or not heparin lots contain the contaminant reported here...
  34. doi Prospective drug safety monitoring using the UK primary-care General Practice Research Database: theoretical framework, feasibility analysis and extrapolation to future scenarios
    Saga Johansson
    AstraZeneca R and D, Molndal, Sweden
    Drug Saf 33:223-32. 2010
    ..However, further improvement in drug safety monitoring requires a shift towards more proactive pharmacoepidemiological methods that can detect adverse drug signals as they occur in the population...
  35. pmc Predicting drug side-effects by chemical systems biology
    Nicholas P Tatonetti
    Training Program in Biomedical Informatics, Stanford University, Stanford, CA 94305, USA
    Genome Biol 10:238. 2009
    ..New approaches to predicting ligand similarity and protein interactions can explain unexpected observations of drug inefficacy or side-effects...
  36. ncbi Adverse drug events in hospitals: a systematic review
    Fabíola Giordani Cano
    Universidade Estadual do Oeste do Paraná, Cascavel, Brasil
    Cad Saude Publica 25:S360-72. 2009
    ..The findings show that ADEs in inpatients are a public health problem. However, further studies are needed to monitor these adverse events in order to effectively promote safe drug use...
  37. pmc Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons
    Lisa A Jackson
    Group Health Research Institute, Seattle, Washington, USA
    BMC Infect Dis 10:71. 2010
    ..The aim of this study was to assess the efficacy, safety, reactogenicity, and immunogenicity of a trivalent inactivated split virion influenza vaccine (TIV) in healthy adults over two influenza seasons in the US...
  38. ncbi Incidence and preventability of adverse drug events among older persons in the ambulatory setting
    Jerry H Gurwitz
    Meyers Primary Care Institute and the University of Massachusetts Medical School, 630 Plantation St, Worcester, Mass 01605, USA
    JAMA 289:1107-16. 2003
    ..Adverse drug events, especially those that may be preventable, are among the most serious concerns about medication use in older persons cared for in the ambulatory clinical setting...
  39. doi Genome-wide association studies in pharmacogenomics
    Ann K Daly
    Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
    Nat Rev Genet 11:241-6. 2010
    ..Since 2007, a range of pharmacogenomics GWA studies have been published that have identified several interesting and novel associations between drug responses or reactions and clinically relevant loci, showing the value of this approach...
  40. pmc Adverse drug event rates in six community hospitals and the potential impact of computerized physician order entry for prevention
    Balthasar L Hug
    Division of General Internal Medicine, Brigham and Women s Hospital, Brigham Circle, 1620 Tremont St, 3rd Floor, Boston, MA, 02120 1613, USA
    J Gen Intern Med 25:31-8. 2010
    ..Medications represent a major cause of harm and are costly for hospitalized patients, but more is known about these issues in large academic hospitals than in smaller hospitals...
  41. doi Experience with a trigger tool for identifying adverse drug events among older adults in ambulatory primary care
    R Singh
    Primary Care Research Institute, State University of New York at Buffalo, Buffalo, New York 14215, USA
    Qual Saf Health Care 18:199-204. 2009
    ..To evaluate the performance of a trigger tool for identifying adverse drug events (ADEs) among older adults in ambulatory primary care practices...
  42. pmc Ten-year trends in hospital admissions for adverse drug reactions in England 1999-2009
    Tai Yin Wu
    Department of Primary Care and Public Health, Imperial College London Charing Cross Campus, London W6 8RP, UK
    J R Soc Med 103:239-50. 2010
    ..Adverse drug reactions (ADR) are an important cause of morbidity and mortality. We analysed trends in hospital admissions associated with ADRs in English hospitals between 1999 and 2008...
  43. pmc Adverse drug reactions in children--a systematic review
    Rebecca Mary Diane Smyth
    School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, England, United Kingdom
    PLoS ONE 7:e24061. 2012
    ..We were particularly interested in understanding how ADRs might be better detected, assessed and avoided...
  44. ncbi The EU-ADR project: preliminary results and perspective
    Gianluca Trifiro
    Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
    Stud Health Technol Inform 148:43-9. 2009
    ..The EU-ADR project aims to exploit different European electronic healthcare records (EHR) databases for drug safety signal detection. In this paper we describe the project framework and the preliminary results...
  45. pmc Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission
    Richard A Cone
    Mucosal Protection Laboratory, Dept of Biophysics, Johns Hopkins University, Baltimore, MD 21218, USA
    BMC Infect Dis 6:90. 2006
    ....
  46. doi Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis
    Lee S Simon
    SDG LLC Consulting, 124 Mt Auburn Street, Cambridge, MA, USA
    Pain 143:238-45. 2009
    ..TDiclo in DMSO vehicle is an effective treatment option for knee osteoarthritis with efficacy similar to, but tolerability better than ODiclo. DMSO vehicle was no more efficacious than placebo...
  47. doi Zebrafish for drug toxicity screening: bridging the in vitro cell-based models and in vivo mammalian models
    Hendrian Sukardi
    National University of Singapore, Department of Biological Sciences, Singapore
    Expert Opin Drug Metab Toxicol 7:579-89. 2011
    ..A number of studies have been conducted to see if these small fish are up to the task of drug toxicity testing, an important rite of passage along the pharmaceutical pipeline.
  48. ncbi The challenge of predicting drug toxicity in silico
    Angelo Vedani
    Biographics Laboratory 3R, Friedensgasse 35, 4056 Basel, Switzerland
    Basic Clin Pharmacol Toxicol 99:195-208. 2006
    ....
  49. doi Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval
    Thijs J Giezen
    Medicines Evaluation Board, The Hague, The Netherlands
    Drug Saf 32:1175-87. 2009
    ....
  50. doi [Adverse drug events in hospitalized elderly patients in a geriatric medicine unit: study of prevalence and risk factors]
    M Cecile
    Service de médecine interne et gériatrie, centre hospitalier régional et universitaire de Marseille, Hopital Sainte Marguerite, 13327 Marseille cedex 9, France
    Rev Med Interne 30:393-400. 2009
    ..Our study compared the parameters of standard geriatric assessment, in the presence or absence of adverse drug events and evaluated the prevalence of adverse drug events in elderly inpatients, the symptoms, and the drugs involved...
  51. doi hERG-related drug toxicity and models for predicting hERG liability and QT prolongation
    Emanuel Raschi
    University of Bologna, Department of Pharmacology, Italy
    Expert Opin Drug Metab Toxicol 5:1005-21. 2009
    ..Therefore, a number of preclinical models have been developed to predict hERG liability early in the drug development process...
  52. doi Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study
    Asia N Rashed
    Centre for Paediatric Pharmacy Research, The School of Pharmacy, University of London, 29 39 Brunswick Square, London WC1N 1AX, UK
    Eur J Clin Pharmacol 68:801-10. 2012
    ..This study aimed to identify risk factors associated with ADRs in hospitalised children and recommend strategies to minimise ADRs...
  53. pmc Identification of adverse drug events: the use of ICD-10 coded diagnoses in routine hospital data
    Jurgen Stausberg
    Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie der LMU, Muchen, Germany
    Dtsch Arztebl Int 107:23-9. 2010
    ..The aim of this study is to examine the potential usefulness of ICD-10 coded diagnoses in routine hospital data for the identification of ADE...
  54. ncbi A drug toxicity death involving propylhexedrine and mitragynine
    Justin M Holler
    Division of Forensic Toxicology, Armed Forces Medical Examiner System, Armed Forces Institute of Pathology, 1413 Research Blvd, Bldg 102, Rockville, Maryland, USA
    J Anal Toxicol 35:54-9. 2011
    ..This is the first known publication of a case report involving propylhexedrine and mitragynine...
  55. doi Cellular immunity as a potential cause of local reactions to booster vaccination with diphtheria and tetanus toxoids and acellular pertussis antigens
    David W Scheifele
    Vaccine Evaluation Center, BC Children s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    Pediatr Infect Dis J 28:985-9. 2009
    ..Cell-mediated immunity (CMI) develops after primary DTaP vaccination and might contribute to local reactions to booster doses, a possibility explored in this study...
  56. doi Pharmacogenomics and drug toxicity
    Yusuke Nakamura
    N Engl J Med 359:856-8. 2008
  57. doi The use of hepatocytes to investigate drug toxicity
    María José Gómez-Lechón
    Unidad de Hepatologia Experimental, Centro de Investigacion, Hospital La Fe, Valencia, Spain
    Methods Mol Biol 640:389-415. 2010
    ..A convenient selection of endpoints allows a multiparametric evaluation of drug toxicity. In this regard, cytomic, proteomic, toxicogenomic and metabonomic approaches help to define patterns of ..
  58. doi A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding
    Shintaro Nakayama
    Drug Metabolism and Pharmacokinetics Research Laboratories, R and D Division, Daiichi Sankyo Co, Ltd, 1 2 58, Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Drug Metab Dispos 37:1970-7. 2009
    The risk of idiosyncratic drug toxicity (IDT) is of great concern to the pharmaceutical industry. Current hypotheses based on retrospective studies suggest that the occurrence of IDT is related to covalent binding and daily dose...
  59. doi Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials
    Ruth Tsang
    Vancouver General Hospital, Vancouver, British Columbia, Canada
    J Clin Epidemiol 62:609-16. 2009
    ..To determine the statistical power to detect potentially clinically significant differences in serious adverse events between drug therapies reported in a sample of randomized controlled trials (RCTs)...
  60. pmc Hospital admissions for 'drug-induced' disorders in England: a study using the Hospital Episodes Statistics (HES) database
    Patrick Waller
    Drug Safety Research Unit, Southampton, UK
    Br J Clin Pharmacol 59:213-9. 2005
    ....
  61. ncbi Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach
    Timothy M D Ebbels
    Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics, Faculty of Medicine, Imperial College London, Sir Alexander Fleming Building, South Kensington, London, United Kingdom
    J Proteome Res 6:4407-22. 2007
    Detection and classification of in vivo drug toxicity is an expensive and time-consuming process...
  62. doi Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients
    Julie Fidlerova
    1st Faculty of Medicine, Institute of Biochemistry and Experimental Oncology, Charles University in Prague, U nemocnice 5, 128 53, Prague 2, Czech Republic
    Cancer Chemother Pharmacol 65:661-9. 2010
    ..The importance of gene variants in dihydropyrimidinase (DPYS) coding for subsequent catabolic enzyme of FP degradation is not fully understood...
  63. doi Epidemiology of recreational drug toxicity in a nightclub environment
    David M Wood
    Guy s and St Thomas Poisons Unit, Guy s and St Thomas NHS Foundation Trust, London, UK
    Subst Use Misuse 44:1495-502. 2009
    Data on 173 individuals with recreational drug toxicity requiring "medical" assistance in a large urban nightclub was collected from September 2007 to January 2008...
  64. ncbi Improving the decision-making process in structural modification of drug candidates: reducing toxicity
    Alaa Eldin F Nassar
    Vion Pharmaceuticals Inc, New Haven, CT, USA
    Drug Discov Today 9:1055-64. 2004
    ..Several examples are included to show how toxicity studies have influenced and guided drug design. Investigations of reactive intermediate formation in subcellular fractions with the use of radiolabeled reagents are also discussed...
  65. ncbi Mechanisms of drug toxicity and relevance to pharmaceutical development
    F Peter Guengerich
    Department of Biochemistry and the Center in Molecular Toxicology, Vanderbilt University School of Medicine, Nashville, TN 37232 0146, USA
    Drug Metab Pharmacokinet 26:3-14. 2011
    ..The causes of drug toxicity can be classified in several ways and include mechanism-based (on-target) toxicity, immune hypersensitivity, ..
  66. ncbi Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity
    David J Browning
    Charlotte Eye, Ear, Nose, and Throat Associates, Charlotte, North Carolina 28210, USA
    Am J Ophthalmol 133:649-56. 2002
    To report hydroxychloroquine and chloroquine retinopathy and consider screening for drug toxicity.
  67. doi Adverse drug reactions detected by stimulated spontaneous reporting in an internal medicine department in Romania
    Andreea Farcas
    University of Medicine and Pharmacy Iuliu Hatieganu, Drug Information Research Center, Pasteur 6, Cluj Napoca, Romania
    Eur J Intern Med 21:453-7. 2010
    ..The aims of this study were to identify the most frequent ADRs recognized by the attending physicians, study their nature and target these ADRs in order to take future preventive measures...
  68. doi Characterization of a gastrointestinal tract microscale cell culture analog used to predict drug toxicity
    Gretchen J Mahler
    School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, New York 14853, USA
    Biotechnol Bioeng 104:193-205. 2009
    ..The microCCA response is also consistent with in vivo measurements in mice. The system should be broadly useful for studies on orally delivered drugs or ingestion of chemicals with potential toxicity...
  69. doi Frequency and nature of adverse drug reactions in elderly in-patients of two Indian medical college hospitals
    A Harugeri
    Department of Pharmacy Practice, J S S College of Pharmacy and J S S Medical College Hospital, J S S University, Mysore, India
    J Postgrad Med 57:189-95. 2011
    ..Although the Indian elderly represent 12.8% of the entire global elderly population, data on prevalence and predictors of ADRs in elderly Indians is extremely limited...
  70. pmc An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole
    F Jacobs
    Hopital Erasme, Universite Libre de Bruxelles ULB, Brussels, Belgium
    Eur J Clin Microbiol Infect Dis 31:1173-9. 2012
    ..This observational study confirms the results of previous clinical trials demonstrating voriconazole as an effective and safe agent for treatment of confirmed acute IA...
  71. doi Adverse drug events in intensive care units: a cross-sectional study of prevalence and risk factors
    Simon Seynaeve
    Department of Critical Care Medicine, Antwerp University Hospital, University of Antwerp, Edegem, Belgium
    Am J Crit Care 20:e131-40. 2011
    ..Adverse drug events are considered determinants of patient safety and quality of care...
  72. ncbi Exploring QSARs with Extended Topochemical Atom (ETA) indices for modeling chemical and drug toxicity
    Kunal Roy
    Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India
    Curr Pharm Des 16:2625-39. 2010
    ..Such models may be used for virtual screening and in silico prediction of toxicities, and if appropriately used, these may be proved helpful for regulatory decision support and decision making processes...
  73. ncbi Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
    Andreas Hochhaus
    III Medizinische Klinik, Medizinische Fakultat Mannheim, Universitat Heidelberg, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    Blood 109:2303-9. 2007
    ..This trial was registered at www.clinicaltrials.gov as CA180013...
  74. ncbi Toxicophores: investigations in drug safety
    Dominic P Williams
    Drug Safety Research Group, Department of Pharmacology and Therapeutics, University of Liverpool, Sherrington Building, Ashton Street, L69 3GE, United Kingdom
    Toxicology 226:1-11. 2006
    ..More importantly, to understand and manipulate these signalling processes will aid in the design of safer therapeutic agents, but also contribute to the clinical management of liver disease...
  75. ncbi Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 111:1060-6. 2008
    ..Increased histone acetylation was observed at all doses. Antioxidant gene expression may confer vorinostat resistance. Further evaluation of vorinostat in AML/MDS is warranted...
  76. doi Prevalence of adverse drug events in ambulatory care: a systematic review
    Stephanie V Taché
    Department of Family and Preventive Medicine, Paracelsus Medical University, Salzburg, Austria
    Ann Pharmacother 45:977-89. 2011
    ....
  77. doi Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States
    Antonia F Stepan
    Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, USA
    Chem Res Toxicol 24:1345-410. 2011
    ..reactive metabolite (RM) formation with new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM formation is routinely examined as part of lead optimization efforts in drug discovery...
  78. pmc Adverse drug events in U.S. adult ambulatory medical care
    Urmimala Sarkar
    Department of Medicine, UCSF Center for Vulnerable Populations, San Francisco General Hospital Medical Services, Division of General Internal Medicine, University of California, San Francisco UCSF, Box 1364, 1001 Potrero, Bldg 10, 3rd Floor, San Francisco, CA 94143 1364, USA
    Health Serv Res 46:1517-33. 2011
    ..To estimate the incidence of adverse drug events (ADEs) associated with health care visits among U.S. adults across all ambulatory settings...
  79. doi Adaptive Bayesian analysis of serum creatinine as a marker for drug-induced renal impairment in an early-phase clinical trial
    Pierre Edouard Sottas
    Covance Central Laboratory Services, Meyrin, Switzerland
    Clin Chem 58:1592-6. 2012
    ..The design of a crossover drug protocol is an opportunity to use study participants as their own control to identify these small but important changes...
  80. ncbi Drug-related problems in hospitals: a review of the recent literature
    Anita Krähenbühl-Melcher
    Hospital Pharmacy, Regionalspital Emmental, Burgdorf, Switzerland
    Drug Saf 30:379-407. 2007
    ....
  81. doi Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World
    Luiz F Oliveira
    Instituto de Pesquisa Clinica Evandro Chagas, IPEC Fiocruz, Brazil
    Acta Trop 118:87-96. 2011
    ..Although closer surveillance is needed for the treatment of cutaneous leishmaniasis, antileishmanial drugs are basically safe and severe side effects requiring the discontinuation of treatment are relatively uncommon...
  82. ncbi [Adverse drug reactions as the reason for visiting an emergency department]
    Carlos Calderón-Ospina
    Departamento de Ciencias Basicas, Facultad de Medicina, Universidad del Rosario, Bogota, Colombia
    Rev Salud Publica (Bogota) 10:315-21. 2008
    ..Determining the prevalence of adverse drug reactions (ADR) as the reason for visiting an emergency department...
  83. doi Off-label and unlicensed medication use and associated adverse drug events in a pediatric emergency department
    Hanna Phan
    Department of Pharmacy Practice and Science, University of Arizona, Tucson, AZ, USA
    Pediatr Emerg Care 26:424-30. 2010
    ....
  84. pmc Focus on headache as an adverse reaction to drugs
    Anna Ferrari
    Headache Centre, Division of Toxicology and Clinical Pharmacology, University Centre for Adaptive Disorders and Headache, Section Modena II University of Modena and Reggio Emilia, Policlinico, Modena 41100, Italy
    J Headache Pain 10:235-9. 2009
    ..Physicians should, therefore, be aware of this issue. Indeed, it is difficult to attribute the diagnosis of adverse drug reaction to a condition, headache, which is also a very common symptom in general population...
  85. ncbi Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice: a study in a French emergency department
    Pascale Olivier
    Department of Clinical Pharmacology, centre Midi Pyrénées de pharmacovigilance, Faculty of Medicine, Toulouse University Hospital, Toulouse, France
    Drug Saf 25:1035-44. 2002
    ..To assess the preventability of adverse drug reactions (ADRs) leading to hospital admissions and to investigate the feasibility of the use of a standardised preventability scale in clinical practice...
  86. doi Adverse drug reactions causing admission to a paediatric hospital: a pilot study
    R M Gallagher
    Institute of Child Health, Royal Liverpool Children s Hospital NHS Foundation Trust, University of Liverpool, Liverpool, UK
    J Clin Pharm Ther 36:194-9. 2011
    ..The objective of this study is to develop methodology to ascertain the current burden of ADRs through a prospective analysis of all unplanned admissions to a paediatric hospital...
  87. ncbi [Preventable adverse drug effects at an emergency department]
    M J Otero López
    Servicio de Farmacia, Hospital Universitario de Salamanca
    Rev Clin Esp 199:796-805. 1999
    ..To determine the incidence and evaluate the preventability of adverse drug events (ADE) associated with visits to the Emergency Department at our hospital and subsequent hospital admissions...
  88. ncbi Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity
    Urs A Boelsterli
    HepaTox Consulting, CH 4148 Pfeffingen, and Institute of Clinical Pharmacy, University of Basel, CH 4031 Basel, Switzerland
    Toxicol Appl Pharmacol 192:307-22. 2003
    ..Increased efforts to identify both patient-specific risk factors and disease-related factors will help to define patient subsets at risk as well as increase the predictability of unexpected hepatotoxicity in drug development...
  89. doi In vitro microscale systems for systematic drug toxicity study
    Jong Hwan Sung
    Department of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, USA
    Bioprocess Biosyst Eng 33:5-19. 2010
    ..We envision that the 'cells-on-a-chip' technology will serve as a valuable link between in vitro and in vivo studies, reducing the demand for animal studies, and making clinical trials more effective...
  90. ncbi National surveillance of emergency department visits for outpatient adverse drug events
    Daniel S Budnitz
    Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    JAMA 296:1858-66. 2006
    ..Adverse drug events are common and often preventable causes of medical injuries. However, timely, nationally representative information on outpatient adverse drug events is limited...
  91. pmc Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer
    M Gusella
    Laboratory of Pharmacology and Molecular Biology, Oncology Department, Azienda ULSS 18 Rovigo, Trecenta, Italy
    Br J Cancer 100:1549-57. 2009
    ..34; P=0.0008) and OS (HR=2.66; P=0.024); (d) the C/C genotype of the MTHFR C677T polymorphism was protective against grade 3-4 toxicity (P=0.040); (e) none of the TYMS polymorphisms could explain 5FU toxicity or clinical outcome...
  92. ncbi Polypharmacy in elderly patients
    Emily R Hajjar
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania 15213, USA
    Am J Geriatr Pharmacother 5:345-51. 2007
    ..Polypharmacy (ie, the use of multiple medications and/or the administration of more medications than are clinically indicated, representing unnecessary drug use) is common among the elderly...
  93. pmc SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome
    Lun Yang
    Bio X Center, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders Ministry of Education, Shanghai Jiao Tong University, Shanghai 200030, PR China
    Nucleic Acids Res 37:W406-12. 2009
    ..The server is freely available at http://SePreSA.Bio-X.cn/...
  94. ncbi Improved therapeutic monitoring with several interventions: a randomized trial
    Adrianne C Feldstein
    Center for Health Research, Kaiser Permanente, Portland, OR, USA
    Arch Intern Med 166:1848-54. 2006
    ..Differences between guideline recommendations and actual frequency of therapeutic laboratory monitoring are substantial. This study evaluated interventions to improve laboratory monitoring at initiation of medication therapy...
  95. ncbi Elucidating mechanisms of drug-induced toxicity
    Daniel C Liebler
    Department of Biochemistry and Center in Molecular Toxicology, Vanderbilt University School of Medicine, 638 Robinson Research Building, 23rd and Pierce Avenues, Nashville, Tennessee 37232 0146, USA
    Nat Rev Drug Discov 4:410-20. 2005
    ..Some of these pathways could be useful as sentinels for toxicity. This article will cover some examples of drug toxicity and the prospects for future technology development.
  96. doi Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer
    Maarten J Deenen
    Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Clin Cancer Res 17:3455-68. 2011
    ..To explore the effect of dihydropyrimidine dehydrogenase (DPD) single nucleotide polymorphisms (SNP) and haplotypes on outcome of capecitabine...
  97. pmc Predicting adverse drug reactions using publicly available PubChem BioAssay data
    Y Pouliot
    Division of Systems Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA
    Clin Pharmacol Ther 90:90-9. 2011
    ..We conclude this paper by predicting that SOC-specific ADRs will be associated with three unapproved or recently introduced drugs...
  98. pmc The effect of an active on-ward participation of hospital pharmacists in Internal Medicine teams on preventable Adverse Drug Events in elderly inpatients: protocol of the WINGS study (Ward-oriented pharmacy in newly admitted geriatric seniors)
    Joanna E Klopotowska
    Department of Hospital Pharmacy, Academic Medical Centre, Amsterdam, The Netherlands
    BMC Health Serv Res 11:124. 2011
    ..Detailed information about the performance of the treating physicians in ADE recognition is scarce...
  99. pmc SuperToxic: a comprehensive database of toxic compounds
    Ulrike Schmidt
    Structural Bioinformatics Group, Institute of Molecular Biology and Bioinformatics, Charite University Medicine Berlin, Arnimallee 22, 14195 Berlin, Germany
    Nucleic Acids Res 37:D295-9. 2009
    ..This database is available online at: http://bioinformatics.charite.de/supertoxic...
  100. ncbi Metabonomics techniques and applications to pharmaceutical research & development
    John C Lindon
    Biological Chemistry, Biomedical Sciences Division, Imperial College London, Sir Alexander Fleming Building, South Kensington, London, SW7 2AZ, UK
    Pharm Res 23:1075-88. 2006
    ..Some discussion is given on the strengths and weaknesses, opportunities of, and threats to metabonomics...
  101. doi Preventability of drug-related harms - part I: a systematic review
    Robin E Ferner
    West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham, UK
    Drug Saf 33:985-94. 2010
    ..We conclude that an approach based on analysis of the mechanisms of adverse reactions and their clinical features could be preferable; such an approach is described in a companion paper (Part II) in this issue of Drug Safety...

Research Grants78

  1. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2013
    ..Also, there will be a measurement of pressure in the eye and thickness of the cornea. To study patients'DNA, the researchers will obtain a bloo..
  2. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2012
    ..Also, there will be a measurement of pressure in the eye and thickness of the cornea. To study patients'DNA, the researchers will obtain a bloo..
  3. Understanding/ Treating Neuropsychiatric Symptoms of Pediatric Physical Illness
    Eva Szigethy; Fiscal Year: 2009
    ..abstract_text> ..
  4. Prevention of Complications in Thalassemia
    Elliott P Vichinsky; Fiscal Year: 2011
    ..Ourmissionalsoincludesmonitorinbgloodsafety amongtransfusion-dependtehnatlassemipaatientsa,ndprovidingoutreachand educationservicestoallat-riskpopulationtshroughoutht estate. ..
  5. SUPPORT CONTRACT FOR THE NTP INTERAGENCY CENTER/VALIDATION OF ALT METHODS
    David Allen; Fiscal Year: 2011
    ..The Panel recommended that studies should be conducted to further characterize the in vitro test methods and that testing strategies should be designed in coordination with ICCVAM. ..
  6. SUPPORT CONTRACT FOR THE NTP INTERAGENCY CENTER/VALIDATION OF ALT METHODS
    David Allen; Fiscal Year: 2012
    ..The Panel recommended that studies should be conducted to further characterize the in vitro test methods and that testing strategies should be designed in coordination with ICCVAM. ..
  7. Sutureless Laparoscopic Partial Nephrectomy Using Laser Tissue Welding: Preclinic
    Yasmin Wadia; Fiscal Year: 2013
    ..Fibro-optic capable: Minimally invasive laparoscopic &robotic applications. ..
  8. Xenoestrogen regulation of Leydig cells
    BENSON TOKUNBO AKINGBEMI; Fiscal Year: 2010
    ..Research training to be afforded by the present application to professional veterinary students will contribute to efforts geared to preparing future veterinarians to meet these challenges. ..
  9. Anti-tumor properties of curcumin in oral cancers: role of thioredoxin reductase
    STEPHEN WILLIAM TUTTLE; Fiscal Year: 2010
    ..However, curcumin has been effective in tumors, such as colon and HNC, where direct access to the drug is possible. The primary aim of this study is to develop curcumin as a chemotherapeutic and radiation sensitizer for treating HNC.. ..
  10. Iron-mediated vascular disease in sickle cell disease.
    John C Wood; Fiscal Year: 2010
    ..This proposal represents an essential first step in the design of a subsequent clinical trial to improve vascular function in SCD patients. ..
  11. Pilot and definitive studies to evaluate Insertional Mutagenesis
    LU TAYLOR; Fiscal Year: 2012
    ..abstract_text> ..
  12. Studies to Evaluate the Toxicological Potential of Test Articles
    LU TAYLOR; Fiscal Year: 2010
    ..abstract_text> ..
  13. Multi-targeted Countermeasures against Acute and Delayed Effects of OP Exposure
    John A Butera; Fiscal Year: 2013
    ..This would set the stage for a final lead optimization campaign focused on identifying pre- clinical leads with well-balanced in vivo PK parameters during an SBIR Phase 2 continuing grant. ..
  14. Enhanced iron removal with peptide linked chelators targeted to ferritin
    Elizabeth C Theil; Fiscal Year: 2010
    ....
  15. Peroxynitrite Decomposition Catalyst and Nitric Oxide Donor for Endotoxemia
    GARRY JOHN SOUTHAN; Fiscal Year: 2012
    ..We will now test this agent in a series of investigations in order to determine the optimal dose, to confirm the mechanism of action, and to establish the window of opportunity after disease onset within which therapy may be initiated. ..
  16. Pathogenesis and Treatment of Liver Disease in Transaldolase Deficiency
    Andras Perl; Fiscal Year: 2013
    ..These studies should generate fundamental new information on the cause and treatment of potentially fatal diseases of the liver. ..
  17. N-methanocarbathymidine (N-MCT) for the Treatment of Herpes and Pox Virus Infecti
    Aquilur Rahman; Fiscal Year: 2010
    ....
  18. Targeted siRNA nanotechnology for intravesical treatment of urologicaldiseases
    Robert M Weiss; Fiscal Year: 2010
    ..Our first test of these nanoparticles will use a mouse model of bladder cancer. Thus, we can determine the therapeutic potential of siRNA for treatment of urologic diseases. ..
  19. Investigating Mechanism of Intracellular Rotational Transport with Optical T
    Jeffrey N Anker; Fiscal Year: 2012
    ..Specifically, we measure toxicity of copper oxide and titanium dioxide which are widely used and have important ramifications for human health. ..
  20. A Soft Topical Antiandrogenic Drug
    Wei Chu Xu; Fiscal Year: 2013
    ..The synthesis and discovery of an optimal locally active androgen antagonist to be applied to the skin to treat acne, alopecia, seborrhea (and hirsutism in women) are the subjects of this application. ..
  21. SUPPORT CONTRACT FOR THE NTP INTERAGENCY CENTER/VALIDATION OF ALT METHODS
    David Allen; Fiscal Year: 2009
    ..NICEATM and ICCVAM will also evaluate non-animal methods and approaches for determining the skin irritation potential of antimicrobial cleaning products...
  22. Trichothecene Toxicity and the Ribotoxic Stress Response
    James J Pestka; Fiscal Year: 2012
    ..Collectively, these outcomes will positively impact public health by providing a scientific basis for generating sound recommendations relative to these important toxins and appropriate remedial actions should exposures occur. ..
  23. Genistein, microRNAs and kidney cancer
    Rajvir Dahiya; Fiscal Year: 2013
    ..Since the goal of this proposal is to investigate the dietary mediated inhibition of RCC through activation of tumor suppressor miRNAs, we believe that the work proposed is highly relevant to Veterans health and the VA mission. ..
  24. Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer
    Paul J Shami; Fiscal Year: 2012
    ..This new drug then goes one step further: it will improve the quality of life for cancer patients, their caregivers and families by providing a significantly more effective and less painful therapy than is currently available. ..
  25. Nanoparticle Coupled Antioxidants for Respiratory Illness in Veterans
    RODNEY JON SCHLOSSER; Fiscal Year: 2013
    ..We will use a murine model of allergic fungal rhinosinusitis with exacerbation by smoke or DEP exposure to determine the efficacy of antiMUC1-SOD/CAT-NPs. ..
  26. Controlling Radiation Injury by TLR5 Agonists
    Andrei V Gudkov; Fiscal Year: 2012
    ..The proposed experiments will provide essential mechanistic insight into the previously observed radio-protective and -mitigative effects of CBLB502. ..
  27. Novel PET imaging agents for early diagnosis of plaque deposition in Alzheimer's
    Padmakar Kulkarni; Fiscal Year: 2010
    ..A successful agent will be highly useful invention not only for early detection of but also for following disease progression and as biomarker for assessing disease-modifying treatments for Alzheimer's disease. ..
  28. Targeting superbugs: discovery and development of new broad-spectrum lipopeptides
    Jian Li; Fiscal Year: 2013
    ..aeruginosa, A. baumannii and K. pneumoniae. Overall, this project targets the urgent global unmet medical need and responds in a timely manner to the recent global call for discovery of new antibiotics: The 10 x '20 Initiative. ..
  29. Comparison of Diesel and Biodiesel Emissions and Health Effects in Underground Mi
    Jefferey L Burgess; Fiscal Year: 2013
    ..Information on the health effects of conversion to biodiesel fuels in occupational and environmental settings will also help to inform future policy decisions. ..
  30. SPEAKER TRAVEL AND SCIENTIFIC SESSION SUPPORT FOR THE TERATOLOGY SOCIETY 50TH
    Christina Chambers; Fiscal Year: 2011
    ..Add Optional Project Narrative File Delete Optional Project Narrative File View Optional Project Narrative File !"#! ..
  31. Human neutrophils, phospholipase A2 and S.aureus: microbial targets and responses
    William M Nauseef; Fiscal Year: 2013
    ..abstract_text> ..
  32. Bisphosphonates in the treatment of chronic kidney disease-mineral bone disease
    Sharon M Moe; Fiscal Year: 2013
    ..Both of these problems may be linked. The purpose of this study is to determine if a commonly used group of drugs, bisphosphonates, may help both bone and heart/blood vessel disease and determine the mechanism the drugs work. ..
  33. MOLECULAR MECHANISMS OF COMPLEX MIXTURE TOXICITY
    Alvaro Puga; Fiscal Year: 2013
    ....
  34. Regulation of Cell Signaling by Human Biliverdin Reductase
    Mahin D Maines; Fiscal Year: 2013
    ..In addition, the enzyme activity is necessary for protection against the fatal "green jaundice". Our work has revealed a novel approach for development of therapeutic interventions in a range of human diseases. ..
  35. Novel diagnostic and safety biomarkers of liver injury and hepatotoxicity
    Stanislav I Svetlov; Fiscal Year: 2010
    ..These assays will provide a novel diagnostic/prognostic tools and serve as "safety biomarkers." according to the FDA. ..
  36. Analysis of gene regulation of Vibrio cholerae during infection
    Jun Zhu; Fiscal Year: 2013
    ..cholerae in vivo survival strategies and shed new light on the host-pathogen interactions that underpin infections by related enteric bacterial pathogens. ..
  37. Tissue-specific delivery of probes by control of membrane trafficking of endoprot
    Blake Peterson; Fiscal Year: 2010
    ....
  38. C5a as an Anti-HIV Microbicidal Candidate
    PHILIPPE ANDRE GALLAY; Fiscal Year: 2013
    ..In addition, protective results would provide proof-of-concept of the usefulness of topically applied microbicides, such as C5A, to prevent genital HIV transmission. ..
  39. Targeting CC-Chemokine Receptor 7 for the prevention of graft-versus-host disease
    JAMES M COGHILL; Fiscal Year: 2013
    ..Through these experiences, Dr. Coghill will obtain the skills necessary to transition to an independent, NIH funded laboratory investigator. ..
  40. Emergency Neurophysiological Assessment Bedside Logic Engine
    Don M Tucker; Fiscal Year: 2010
    ..g,. seizure, burst-suppression coma, drug toxicity, vasospasm, focal slowing due to hematoma)...
  41. Molecular mechanisms of lung disease in ataxia telangiectasia
    JoAnn M Sekiguchi; Fiscal Year: 2013
    ..abstract_text> ..
  42. Small Molecule targeting of NADPH oxidase in neutrophils
    Marie Dominique Filippi; Fiscal Year: 2010
    ..Therefore, our study will help delivering a novel pharmaceutical target, and suitable lead compounds for the treatment of lung inflammation, such as ALI and ARDS. ..
  43. Mechanism-Based Discovery of Protectants Against Iron-Dependant Oxidative Injury
    JUSTIN M SCHWARTZ; Fiscal Year: 2011
    ..My project proposes to better understand the role of iron mobilization from lysosomes to mitochondria in ischemia/reperfusion injury and to develop novel therapies to mitigate or eliminate damage from this condition. ..
  44. Arsenic Trioxide and Acute Myeloid Leukemia
    Yongkui Jing; Fiscal Year: 2012
    ..Our goal will be to utilize As2O3 in combination with 4 HPR or EA analogs in clinical trials in patients with refractory, secondary or in elderly patients with acute myelogenous leukemia. ..
  45. Systemic AA Amyloidosis Inhibitors
    ALAN D SNOW; Fiscal Year: 2010
    ..In this project we intend to develop a new drug (and back-up) for effective treatment of ~100,000 cases of systemic amyloidosis in the USA, for which today there is no real treatment whatsoever. ..
  46. N-methanocarbathymidine (N-MCT) for the Treatment of Herpes and Pox Virus Infecti
    Aquilur Rahman; Fiscal Year: 2013
    ....
  47. Overcoming Temozolomide Resistance using MGMT-targeting Spherical Nucleic Acids
    TIMOTHY L SITA; Fiscal Year: 2013
    ..In vivo studies with orthotopic GBM mouse models will assess the combination treatment of MGMTi-SNAs and TMZ;we intend to (1) enhance intratumoral apoptosis, (2) reduce glioma formation, and (3) increase survival time. ..
  48. Nitric Oxide Restoration &Heme Detoxification as Adjunctive Therapies for Cerebr
    LEONARDO JOSE DE MOURA CARVALHO; Fiscal Year: 2012
    ..In this proposal, we intend to develop, using an animal model, adjunctive therapies based on nitric oxide restoration and/or heme detoxification that can be potentially translated into clinical use. ..
  49. Microsomal Cytochromes P450 and their Interactions with their Redox Partners
    Lucy A Waskell; Fiscal Year: 2013
    ....
  50. Protection of Brain Injury from Cyanide Poisoning by Carnosic Acid
    Stuart A Lipton; Fiscal Year: 2013
    ..To investigate neuroprotective effects of CA in an in vitro model of cyanide poisoning. Specific Aim 2. To examine neuroprotective effects of CA in an in vivo mouse model mimicking the effects of cyanide ingestion. ..
  51. Transplatin: A Novel Agent to Mitigate Cisplatin Toxicity
    Vickram Ramkumar; Fiscal Year: 2013
    ..Overall, we believe that this study will provide the basis for the use of transplatin to alleviate cisplatin toxicities in cancer patients. ..
  52. NITROGEN HETEROCYCLES: METABOLIC EFFECTS AND TOXICITY
    Raymond F Novak; Fiscal Year: 2010
    ....
  53. Predicting Bilirubin-induced Auditory Toxicity in Infants with Severe Jaundice
    Sanjiv B Amin; Fiscal Year: 2010
    ....
  54. Inhibiting Mucosal HIV-1 Transmission by Host Cell RNA Interference
    Alexandra L Howell; Fiscal Year: 2013
    ..S. Veteran and active military population, and because of the increasing incidence of this disease in the U.S. ..
  55. Characterization of new toxins (YmgD and YdfD) from E.coli, targeting cell wall
    Hisako Masuda; Fiscal Year: 2012
    ....
  56. Preclinical drug trial in mouse models of inflammation
    Kanneboyina Nagaraju; Fiscal Year: 2011
    ..This proposal will help to train a pool of talented young scientists to pursue mouse model research and accelerate development of therapies for inflammatory diseases. ..
  57. CHEMISTRY AND BIOLOGY OF PLATINUM ANTICANCER DRUGS
    Stephen J Lippard; Fiscal Year: 2013
    ..The knowledge acquired will be used to design, synthesize, and evaluate new anticancer drug candidates for targeting and destroying tumors. ..
  58. Alcohol-Induced Bone Resorption: The Role of Oxidative Stress
    Martin J J Ronis; Fiscal Year: 2013
    ..In addition, in vivo studies will be conducted to examine the ability of antioxidants to block EtOH-induced bone resorption. ..
  59. Improved Adventitial Sirolimus Therapy for Peripheral Artery Restenosis
    KIRK SEWARD; Fiscal Year: 2010
    ....
  60. Novel Zebrafish Models to Study Toxicity of PCBs and Pesticides During Pregnancy
    Lisa Satterwhite; Fiscal Year: 2009
    ....
  61. The Electricidal Effect, a Novel Anti-Biofilm Strategy
    Robin Patel; Fiscal Year: 2013
    ..This new strategy would overcome the resistance to traditional antibiotics of microorganisms in biofilms. ..
  62. Killed But Metabolically Active Leishmania: a novel protozoan vaccine technology
    Noah Craft; Fiscal Year: 2009
    ..If effective, this technology could potentially be applied to other infectious agents such as malaria and tuberculosis in the future. ..
  63. Depot calcineurin inhibitors to prevent graft rejection
    Thomas J Smith; Fiscal Year: 2010
    ..In Phase 2 we propose to optimize the parameters of the delivery system, manufacture it according to FDA standards, and confirm its delivery profile and safety in further animal studies. ..
  64. Absorption, distribution, metabolism, excretion (ADME) of chemicals in mammals
    Rochelle W Tyl; Fiscal Year: 2009
    ..N-dimethylacetoacetamide were completed during this reporting period and final reports are being prepared. ..
  65. Attenuating the retinal and CNS adverse effects of vigabatrin with NKCC1 inhibito
    Frances E Jensen; Fiscal Year: 2010
    ....
  66. Developing a prediction model for vincristine-induced peripheral neuropathy
    Jamie L Renbarger; Fiscal Year: 2010
    ..Once the correlation between genetics and vincristine neurotoxicity fully elucidated, it will be possible to individualize vincristine dosing using genetic information to optimize therapeutic efficacy while minimizing toxicity. ..
  67. FDG-PET and V/Q SPECT Acquired During Radiation to Predict Outcomes in Lung Cance
    Feng Ming Kong; Fiscal Year: 2009
    ..If successful, future radiation therapy could be personalized based on their response to radiation and treatment gain could be maximized. ..
  68. CARDIAC & VASCULAR TOXICITY OF COCAINE
    James Morgan; Fiscal Year: 1991
    ..We anticipate that the results of these studies will not only clarify the pathophysiologic basis of cocaine's cardiovascular toxicity but will provide a rational basis for preventative measures and therapeutic interventions...
  69. Computational and Cell Culture Models for Mucus Clearance
    Richard Superfine; Fiscal Year: 2010
    ..The availability of a cell culture-based clearance assay coupled with an in- silico computational model will reduce the reliance on animal models and more accurately predict the consequences of toxins on human health. ..
  70. PHARMACOLOGY AND EFFICACY OF NOVEL TAXOL FORMULATIONS
    ROBERT STRAUBINGER; Fiscal Year: 1999
    ....
  71. Development of Transdermal Films for the the Delivery of HIV Therapeutics
    Anthony Sang Won Ham; Fiscal Year: 2010
    ..The research to be performed will include development of the transdermal film and the evaluation of its ability to deliver a therapeutic amount of IQP-0410 over long periods of time. ..
  72. GENOTOXICITY IN CYP1A2 DEFICIENT TRANSGENIC MICE
    Daniel Nebert; Fiscal Year: 2002
    ..S. population. ..
  73. Molecular Regulation of Alpha-Synuclein Misfolding and Toxicity in Two Yeast Mode
    SHUBHIK DEBBURMAN; Fiscal Year: 2009
    ....
  74. BILIRUBIN TOXICITY IN THE AUDITORY SYSTEM
    Steven Shapiro; Fiscal Year: 2005
    ..The findings of the proposed research should lead to improved noninvasive procedures for predicting, preventing, and treating the neurological and audiological complications of bilirubin toxicity in human newborns. ..
  75. DOSIMETRY IN CHILDREN AND YOUNG ADULTS WITH NEUROBLASTOMA OR NEUROENDOCRINE TUMOR
    M SUE O DORISIO; Fiscal Year: 2009
    ..Our long-term goal is to develop patient specific, combination radiotherapy for pediatric tumors as a major step forward from the current approach of delivering an "average patient" radiation dose using a single agent. ..
  76. ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION (ADME) IN MAMMALS
    Jacob McDonald; Fiscal Year: 2012
    ..There is no ADME data in the literature for DMDEE. Therefore, the ADME of this is investigated in the current contract in rodents with special attention to the formation of carcinogenic metabolite N-nitrosomorpholine. ..
  77. Chromatin Modifications and Vulnerability to Glutamate Toxicity
    ALEXEI D KONDRATYEV; Fiscal Year: 2010
    ..This proposal will examine these mechanisms and will lay the foundation for identification of new targets for therapy of a broad variety of neurological conditions relevant to excitotoxicity. ..
  78. ANESTHETIC TOXICITY--MECHANISMS AND PREVENTION
    Evan Kharasch; Fiscal Year: 1999
    ..More importantly, potentially bioactivated anesthetics or protoxins may be rationally designed to avoid this metabolic hazard. ..